Multimedia

Multimedia

Sound Bites and exclusive interviews with researchers, commentators, and experts in the field.

Pulling Back the Curtain: Dan Pollyea, MD, MS

In more from our interview with Dan Pollyea, MD, MS, he shares what he learned from growing up watching his father practice medicine and the simple...

Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism

Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...

Ravulizumab: A New Treatment Option for PNH?

Austin Kulasekararaj, MD, MBBS, MRCP, FRCPath, shares results from a phase III study comparing ravulizumab with eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

A Rapid, Inexpensive Screening Test for Sickle Cell Disease in Uganda

Erik Serrao, PhD, discusses the HemoTypeSC test, which provides a rapid, cost-effective screening method for sickle cell disease in newborns living in limited-resource settings. Editor’s...

Elotuzumab Combination Prevents Progression from Smoldering to Symptomatic Myeloma

Irene Ghobrial, MD, shares results from a phase II trial, in which 84 percent of patients with high-risk smoldering multiple myeloma responded to treatment...

PERIOP 2: Do Patients at High Risk for Arterial Thromboembolism Need LMWH Bridging?

Michael Kovacs, MD, discusses results from the PERIOP 2 trial, which found that post-procedure bridging with low-molecular weight heparin during warfarin interruption offered no...

A New Personalized Risk-Stratification Model for Myelodysplastic Syndromes

Dr. Nazha discusses a new tool for the risk-stratification of patients with myelodysplastic syndromes, which outperformed traditional risk models.

Evaluating a Venetoclax and Carfilzomib Combination in Myeloma

Luciano Costa, MD, PhD, shares findings from a phase II study, in which the combination appeared tolerable and effective in patients with relapsed/refractory myeloma.

Is Luspatercept a New Option for Patients With MDS?

Dr. List discusses results from the MEDALIST trial in patients with transfusion-dependent myelodysplastic syndromes, which were presented as a plenary abstract at the 2018...

Ibrutinib Outperforms Chemoimmunotherapy in CLL

Dr. Woyach shares findings from her plenary abstract, in which ibrutinib improved survival outcomes in older patients with chronic lymphocytic leukemia, compared with a...
Advertisement

Current Issue

December 2019, Volume 5, Issue 15

This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.